All Stories

  1. Non-Hodgkin Lymphomas
  2. Cancer in Adolescents and Young Adults in Countries with Limited Resources
  3. Planning cancer control—the view of an NGO
  4. Paediatric cancer in low-income and middle-income countries
  5. New policies to address the global burden of childhood cancers
  6. An Introduction to Burkitt Lymphoma
  7. Special Considerations in Low and Middle Income Countries
  8. Treatment of Burkitt lymphoma in equatorial Africa using a simple three‐drug combination followed by a salvage regimen for patients with persistent or recurrent disease
  9. Epidemiology: clues to the pathogenesis of Burkitt lymphoma
  10. Aggressive B-Cell Lymphomas
  11. Towards Curative Therapy in Burkitt Lymphoma: The Role of Early African Studies in Demonstrating the Value of Combination Therapy and CNS Prophylaxis
  12. Diagnosis of Burkitt lymphoma using an algorithmic approach – applicable in both resource‐poor and resource‐rich countries
  13. Lymphomas in sub‐Saharan Africa – what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?
  14. Childhood T-lineage acute lymphoblastic leukemia: Management and outcome at a tertiary care center in North India
  15. Epidemiology and management of lymphoma in low‐income countries
  16. Cancer funding in developing countries: the next health-care crisis?
  17. The World Cancer Declaration: is the world catching up?
  18. The Lymphoid Neoplasms 3ed
  19. Chronic lymphoid leukemias and μ heavy chain disease
  20. Introduction to the lymphoid neoplasms
  21. Historical perspective
  22. Pattern of Relapse in Childhood ALL: Challenges and Lessons From a Uniform Treatment Protocol
  23. Denis Burkitt and the African lymphoma
  24. Lessons from clinical trials in African Burkitt lymphoma
  25. It Is Time to Include Cancer and Other Noncommunicable Diseases in the Millennium Development Goals
  26. Outcomes of Patients With Burkitt Lymphoma Older Than Age 40 Treated With Intensive Chemotherapeutic Regimens
  27. Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study
  28. Non‐Hodgkin Lymphomas
  29. Building capacity for cancer control in developing countries: the need for a paradigm shift
  30. Treatment of Burkitt lymphoma in children and adults: Lessons from Africa
  31. High level expression of N-acetylgluosamine-6-O-sulfotransferase is characteristic of a subgroup of paediatric precursor-B acute lymphoblastic leukaemia
  32. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year peroid
  33. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation
  34. Modified Magrath Regimens for Adults with Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy with Decreased Toxicity
  35. Differences in the Expression of Apoptotic Proteins in Burkitt's Lymphoma Cell Lines: Potential Models for Screening Apoptosis-Inducing Agents
  36. Chemotherapy in developing countries—is less better?
  37. Frequencies of the major subgroups of precursor B-cell acute lymphoblastic leukemia in Indian children differ from the West
  38. Molecular Characteristics of Diffuse Large-B-Cell Lymphoma
  39. Expression of P53 and Bcl-2 Proteins in T-cell Lymphoblastic Lymphoma: Prognostic Implications
  40. Editorial comment on detection of Epstein–Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction by Wagner and colleagues
  41. Burkitt's/Burkitt's-Like Lymphoma Presenting as Bacterial Sinusitis in Two HIV-Infected Children
  42. Incidence, clinical characteristics and early treatment outcome in Indian patients of childhood acute lymphoblastic leukemia with ALL-1 gene rearrangement
  43. Non-Hodgkin Lymphomas
  44. Significance of MDR1, MRP1, GSTπ and GSTμ mRNA expression in acute lymphoblastic leukemia in Indian patients
  45. Pediatric oncology in developing countries: Development of an alliance of stakeholders
  46. Expression of EBV Encoded Nuclear Small Non-Polyadenylated RNA (EBER) Molecules in 32 Cases of Childhood Burkitt's Lymphoma from Israel
  47. Pediatric oncology in developing countries: Development of an alliance of stakeholders
  48. Impact of Chemotherapy for AIDS‐Related Malignancies in Pediatric HIV Disease
  49. Pattern of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements in childhood acute lymphoblastic leukemia in India
  50. Loss of Y Chromosome in Bilharzial Bladder Cancer
  51. Molecular profile of Epstein–Barr virus infection in HHV-8-positive primary effusion lymphoma
  52. Association of Burkitt's Lymphoma with the Epstein-Barr Virus in Two Developing Countries
  53. Breast Cancer: a New Epstein-Barr Virus-Associated Disease?
  54. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: High prevalence of p53 overexpression
  55. Comparative incidence of the rearrangements of TEL/AML1 and ALL1 genes in pediatric precursor B acute lymphoblastic leukemias in India.
  56. Gene Therapy in the Treatment of Cancer
  57. Preface
  58. Introduction: gene therapy approaches to cancer
  59. Precursor B-Lymphoblastic Lymphoma Presenting as a Solitary Bone Tumor and Mimicking Ewing's Sarcoma
  60. p53 Expression in Langerhans Cell Histiocytosis
  61. Limiting Therapy for Limited Childhood Non-Hodgkin's Lymphoma
  62. Non-Hodgkin's Lymphomas: Epidemiology and Treatment
  63. Expression of p53 in pediatric lymphomas from Mexico
  64. NON-HODGKIN'S LYMPHOMA
  65. RESULTS OF A TREATMENT PROTOCOL FOR CHILDREN WITH HIV AND NON-HODGKIN'S LYMPHOMAS (NHLS).
  66. The treatment of pediatric lymphomas: Paradigms to plagiarize?
  67. 5 Management of histologically aggressive lymphomas with a high risk of CNS disease
  68. Combination chemotherapy for advanced bilharzial bladder carcinoma
  69. Use of Epstein-Barr Virus Nuclear Antigen-1 in Targeted Therapy of EBV-Associated Neoplasia
  70. Treatment of Patients with High Grade Non-Hodgkin's Lymphomas and Central Nervous System Involvement: Is Radiation an Essential Component of Therapy?
  71. P53 MUTATIONS IN EGYPTIAN BLADDER-CANCER
  72. 1241 Impact of improved supportive care on treatment outcome in acute lymphoblastic leukemia—an indian experience
  73. The investigation of epstein–barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt. Epidemiologic correlations
  74. Bone-marrow transplantation
  75. Bone marrow transplantation for leukaemia: a lame stalking horse for use of high-technology medical care
  76. Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy
  77. Elevated levels of p53 protein in adrenocortical carcinomas from Costa Rica
  78. Mutations in the Coding Region of c-myc Occur Independently of Mutations in the Regulatory Regions and are Predominantly Associated with myc/lg Translocation
  79. BOOK REVIEW
  80. Binding and suppression of the Myc transcriptional activation domain by p107
  81. PROGNOSTIC-SIGNIFICANCE OF P53 MUTATIONS IN SMALL NON-CLEAVED CELL LYMPHOMAS
  82. Targeted approaches to cancer therapy: Meeting held at stone house, NIH, bethesda, md, January 11–12, 1993
  83. Adult Acute Lymphoblastic Leukemia: Results of an Aggressive Regimen in India
  84. Prospects for the therapeutic use of antisense oligonucleotides in malignant lymphomas
  85. A de novo p53 germline mutation affecting codon 151 in a six year old child with multiple tumors
  86. Infection Analysis in Acute Lymphoblastic Leukemia: A Report of 499 Consecutive Episodes in India
  87. Point mutations in the c–Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas
  88. Cancer in Developing Countries: Opportunity and Challenge
  89. MOLECULAR CHARACTERIZATION OF SCL REARRANGEMENTS IN T-CELL ALL FROM INDIA AND EGYPT
  90. Replicative viral DNA in Epstein-Barr virus associated Burkitt's lymphoma biopsies
  91. The role of gallium-67 tumour scintigraphy in patients with small, non-cleaved cell lymphoma
  92. Heterotransplantation of Human Burkitt’s Lymphoma Cell Lines in Athymic Nude Mice: Tumor-Host Relationships
  93. Burkitt's lymphoma between African and American types in Turkish children: Clinical, viral (EBV), and molecular studies
  94. PCR detection of a neutral CGA/CGG dimorphism in exon 6 of the human p53 gene
  95. A novel mutation in the p53 gene in a Burkitt's lymphoma cell line
  96. Burkitt’s Lymphoma Cells Frequently Carry Monoallelic DJ Rearrangements
  97. A chemiluminescent assay for quantitation of β-galactosidase in the femtogram range: Application to quantitation of β-galactosidase in lacZ-transfected cells
  98. Ifosfamide in the treatment of high‐grade recurrent non‐hodgkin's lymphomas
  99. Prolonged disease‐free survival in pediatric non‐hodgkin's lymphoma using ifosfamide‐containing combination chemotherapy
  100. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
  101. Workshop on pediatric lymphomas: Current results and prospects
  102. Workshop on pediatric lymphomas: Current results and prospects
  103. African Burkittʼs Lymphoma
  104. Inhibition of the EBV Lytic Cycle by Sequence Specific Antisense Oligonucleotides
  105. Advances in the Understanding of EBV Associated Lymphoproliferative Disorders
  106. Identification of p53 gene abnormalities in acute lymphoblastic leukemia of childhood
  107. Neo-Adjuvant chemotherapy : Epirubicin in invasive bladder cancer ; four-year follow-up
  108. Book Review The Non-Hodgkin's Lymphomas Edited by Ian T. Magrath. 430 pp., illustrated. Baltimore, Williams and Wilkins, 1990. $72.50.
  109. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide
  110. The Pathogenesis of Burkitt's Lymphoma
  111. Phenotypic analysis of T-cell acute lymphoblastic leukemia in Egypt
  112. Relative Predispositional Effect of a PADPRP Marker Allele in B-Cell and Some Non B-Cell Malignancies
  113. Immunoglobulin Delta Expression in Burkitt's Lymphoma Cell Lines
  114. Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen
  115. BOOK REVIEWS
  116. New Directions in Cancer Treatment
  117. Infectious Mononucleosis and Malignant Neoplasia
  118. Immunological sub types of Egyptian acute lymphoblastic leukemia
  119. Bone marrow involvement in young patients with non‐Hodgkin's lymphoma: The importance of multiple bone marrow samples for accurate staging
  120. Childhood Non-Hodgkin’s Lymphomas
  121. New Directions in Cancer Treatment: An Overview
  122. Prospects for the Development of Antineoplastic Therapy Based on Molecular Pathology
  123. The molecular analysis of chromosomal translocations as a diagnostic, epidemiological and potentially prognostic tool in lymphoid neoplasia
  124. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma.
  125. Testicular Involvement in Young Patients with Non-Hodgkinʼs Lymphoma
  126. Significance of Chromosome 8 Breakpoint Location in Burkitt’s Lymphoma: Correlation with Geographical Origin and Association with Epstein-Barr Virus
  127. Immunogenetics Immunogenetics: Its Application to Clinical Medicine Takehiko Sasazuki Tomio Tadi
  128. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.
  129. Treatment of recurrent sarcomas and pediatric solid tumors with ifosfamide (IF)
  130. Characterization of Burkitt’s Lymphoma Cell Lines with Monoclonal Antibodies Using an ELISA Technique
  131. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people
  132. Very high dose cyclophosphamide with imidazole carboximide and vineristine sulf ate in the treatment of Stasre IV neuroblastoma
  133. Myelopathy following intrathecal chemotherapy in a patient with extensive burkitt's lymphoma and altered immune status
  134. Clinical and Pathobiological Features of Burkitt’s Lymphoma and their Relevance to Treatment
  135. Chromosomal orientation of the lambda light chain locus: Vλ is proximal to Cλ in 22q11
  136. Characteristics and results of treatment of non-Hodgkin’s lymphoma in young people — Experience of the Pediatric Branch, NCI, USA
  137. HIGH‐GRADE NON‐HODGKIN'S LYMPHOMA IN PATIENTS WITH AIDSa
  138. Induction of plasmacytoid differentiation by phorbol ester in B-cell lymphoma cell lines bearing 8;14 translocations.
  139. Jaw involvement in American Burkitt's lymphoma
  140. Burkitt’s Lymphoma: Clinical Aspects and Treatment
  141. Synthesis of kappa light chains by cell lines containing an 8;22 chromosomal translocation derived from a male homosexual with Burkitt's lymphoma
  142. Gastric manifestations of North American Burkitt's lymphoma
  143. Fluorescence polarization as a parameter of plasma lipids in patients with hematologic malignancies
  144. Undifferentiated lymphoma cells respond to PWM in the presence of theophylline or helper T cells
  145. Classification of cell lines derived from undifferentiated lymphomas according to their expression of complement and Epstein-Barr virus receptors: Implications for the relationship between African and American Burkitt's lymphoma
  146. The Role of Surgery in the Management of American Burkittʼs Lymphoma and Its Treatment
  147. Plasma lipid alterations in leukemia and lymphoma
  148. The American Burkitt's lymphoma registry:Eight years' experience
  149. Burkitt cell leukemia without abnormalities of chromosomes No. 8 and 14
  150. HYPOTHESIS: THE ENVIRONMENT IS A MAJOR DETERMINANT OF THE IMMUNOLOGICAL SUB‐TYPE OF LYMPHOMA AND ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN
  151. Renal and Metabolic Complications of Undifferentiated and Lymphoblastic Lymphomas
  152. CT of American Burkitt lymphoma
  153. The Epstein-Barr Virus. M. A. Epstein B. G. Achong
  154. Long‐term experience with burkitt's lymphoma in uganda
  155. B Cell Differentiation and Immunoregulatory T Cell Function in Human Cord Blood Lymphocytes
  156. Acute tumor lysis syndrome
  157. Prognostic factors in Burkitt's lymphoma importance of total tumor burden
  158. Bone marrow involvement in Burkitt's lymphoma and its relationship to acute B-cell leukemia
  159. Activation of Suppressor T Cells during Epstein-Barr-Virus-Induced Infectious Mononucleosis
  160. CURE OF BURKITT'S LYMPHOMA Ten-year Follow-up of 157 Ugandan Patients
  161. Enhancement of Epstein-Barr virus replication in producer cell lines by a combination of low temperature and corticosteroids
  162. Ultrasound evaluation of american burkitt's lymphoma
  163. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer
  164. Tumor lysis pancreatitis
  165. Childhood Hodgkin's disease in Uganda.A ten year experience
  166. A new tumour-derived transforming strain of Epstein–Barr virus
  167. Fc IgM receptors on human lymphoblastoid B cell lines
  168. Hypercalcemia with suppressed parathyroid hormone in Burkitt's lymphoma
  169. Prolonged complete remission following high dose chemotherapy of burkitt's lymphoma in relapse
  170. Immunosuppression in burkitt's lymphoma. II. Peripheral blood lymphocyte populations related to clinical status
  171. Treatment of Burkitt's lymphoma: Randomized clinical trial of single‐agent versus combination chemotherapy
  172. Failure of BCG immunostimulation to affect the clinical course of Burkitt's lymphoma.
  173. Antibodies to Epstein–Barr-Virus Antigens before and after the Development of Burkitt's Lymphoma in a Patient Treated for Hodgkin's Disease
  174. HL–A and Burkitt's Tumour – A Study in Uganda
  175. CHEMOTHERAPY OF HODGKIN'S DISEASE
  176. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)
  177. Immunosuppression in Burkitt's lymphoma. I. Cutaneous reactivity to recall antigens: Alterations induced by a tumour burden and by BCG administration
  178. Surgical Reduction of Tumour Bulk in Management of Abdominal Burkitt's Lymphoma
  179. Burkitt's lymphoma: a B or T cell tumour?
  180. Preliminary Results of a Randomized Trial of BCG Immunotherapy in Burkitt’s Lymphoma
  181. Burkitt's Tumors Contain Particles Encapsulating RNA-Instructed DNA Polymerase and High Molecular Weight Virus-Related RNA
  182. Skin ulceration caused by Salmonella dublin.
  183. Standardization of the Leucocyte Migration Test
  184. Intensive chemotherapy in patients with generalized Burkitt's lymphoma
  185. CHEMOTHERAPY OF CHILDHOOD HODGKIN'S DISEASE IN UGANDA
  186. Survival of candida septicaemia treated with amphotericin B
  187. Medical Presentations of Choriocarcinoma
  188. INTRATHECAL METHOTREXATE
  189. Principles of transformation-directed cancer therapy
  190. Vectors for cancer gene therapy
  191. B-Cell Lymphoma/Burkitt Lymphoma